Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures in patients 2 years of age and older with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
**Lennox-Gastaut Syndrome (LGS):**
* **Initiation:** 5 mg twice daily (BID).
* **Titration:** Increase dose by 5 mg to 10 mg every week to a maximum of 20 mg BID.
* **Maximum Dose:** 20 mg BID (40 mg daily).
## Pediatric Dosing
**Lennox-Gastaut Syndrome (LGS) - Age 2 years and older:**
* **Initiation:** 5 mg BID.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week to a maximum of 10 mg BID for patients weighing less than 30 kg, or 20 mg BID for patients weighing 30 kg or more.
* **Maximum Dose:** 10 mg BID (20 mg daily) for patients weighing less than 30 kg; 20 mg BID (40 mg daily) for patients weighing 30 kg or more.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosing recommendations are available, but dose reduction may be necessary.
* **Renal Impairment:** Use with caution. No specific dosing recommendations are available, but dose reduction may be necessary.
* **Concomitant Medications:** Clobazam is a CYP2C19 substrate. Avoid strong CYP2C19 inhibitors or inducers. Dose reduction may be needed when co-administered with certain other antiepileptic drugs (e.g., valproic acid, stiripentol).
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, upper respiratory tract infection, pneumonia, ataxia, fatigue.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, cognitive impairment, paradoxical reactions (increased seizure frequency, excitation).
## Key Drug Interactions
* **CNS Depressants:** Alcohol, opioids, other sedating medications may potentiate CNS depressant effects (e.g., excessive sedation, respiratory depression).
* **CYP2C19 Inhibitors/Inducers:** Strong inhibitors (e.g., fluconazole) may increase clobazam levels. Strong inducers (e.g., rifampin) may decrease clobazam levels.
* **Valproic Acid:** Increased valproic acid levels have been reported, potentially increasing the risk of valproic acid toxicity.
* **Stiripentol:** May increase clobazam plasma concentrations.
## Monitoring
* Monitor for signs of suicidal behavior and ideation.
* Assess for somnolence and sedation, especially during initiation and dose adjustments.
* Monitor for respiratory depression, particularly in patients with pre-existing respiratory conditions or when co-administered with other respiratory depressants.
* Observe for signs of dependence and withdrawal upon discontinuation.
* Monitor liver and renal function if clinically indicated.
## Clinical Pearls
* Clobazam can be taken with or without food.
* Due to the risk of dependence and withdrawal, abrupt discontinuation should be avoided. Taper the dose gradually.
* The active metabolite of clobazam, N-desmethylclobazam, has a significantly longer half-life and contributes to the overall pharmacological effect.
* Particular caution is advised in elderly patients due to increased sensitivity to benzodiazepines.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the current official prescribing information and institutional protocols before making any clinical decisions.
